Mining the human immune response for innovative monoclonal antibodies to combat the growing antibiotic resistance crisis.

About Us

Message from the CEO on COVID-19


“We are closely monitoring the COVID-19 pandemic and have recently instituted a number of measures to protect the safety and well-being of the patients involved in our AR-301 and AR-501 clinical programs, as well as our employees. We are working with our contract research organizations to support physicians and hospitals in devoting their resources to treating COVID-19 patients and avoid exposing study volunteers to unnecessary risk. This pandemic is creating a worldwide shortage in mechanical ventilators that are needed to support infected patients. As our global Phase 3 clinical study is on ventilator associated pneumonia patients, we are working diligently to evaluate the pandemic and expect to provide guidance of COVID-19’s impact on our on-going and planned clinical studies.


Separately, I am pleased to announce that our research staff have been hard at work to leverage our scientific strength and ingenuity to develop differentiated, effective therapeutic and prophylactic solutions to curtailing the deadly impact of COVID-19, and hope to announce our preliminary results in due course.”

Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. Our scientists and leadership team have a proven track record of innovation and successful drug development of therapeutic candidates from early discovery to commercial implementation.

The Company’s mission is to introduce much needed innovations to infectious disease treatment using an anti-infective product portfolio that includes four (4) clinical stage and two preclinical drug candidates.  Our antimicrobial product candidates are highly differentiated from conventional antibiotics in mechanisms of action, and are being developed using clinical study designs that allow for clear demonstration of superiority over standard of care antibiotics.


Our products target infectious diseases that have a significant impact on life expectancy and address acute medical needs including:


  • Hospital Acquired Infections (Ventilator Associated Pneumonia)
  • Cystic Fibrosis
  • Blood Stream Infections

AR-301 (SalvecinTM) is a fully human monoclonal IgG1 antibody that specifically targets S. aureus alpha-toxin, a toxic protein secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA). AR-301 protects against alpha-toxin dependent destruction, preserving the human immune cells.

AR-101 (AerumabTM) is a highly specific monoclonal antibody targeted against P. aeruginosa lipopolysaccharide serotype O11, which accounts for ~22% of all P. aeruginosa hospital-acquired infections worldwide. Binding of AR-101 to P. aeruginosa bacteria facilitates human complement binding and improves immune recognition and destruction by circulating human phagocytes.

AR-501 is a novel small molecule anti-infective that diversifies our mAb immunotherapy-focused product portfolio. AR-501 is an inhalable form of gallium citrate, which acts as an iron analog to starve bacteria of iron. Gallium is believed to inhibit multiple iron-dependent synthetic and metabolic pathways required for pathogenicity. As with our monoclonal antibody programs, the mechanism of action of AR-501 is different from all antibiotics, and is effective against antibiotic resistant bacteria.


Complementing our current clinical pipeline, we have two additional drug candidates in preclinical development. AR-201 is a human IgG1 mAb directed against the F-protein of respiratory syncytial virus (RSV). AR-401 is a mAb discovery program to treat infections caused by the Gram-negative bacterium Acinetobacter baumannii.



In virtually all infectious diseases, there is a subset of disease-free individuals that may be generating rare, potent, protective immune responses to even the most lethal pathogens. Human monoclonal antibodies are often the key protective components. Our discovery technology platform aims to find and transform these components into innovative therapies to treat the masses.

News Releases

Welcome to the breaking news section for Aridis Pharmaceuticals. You can view ALL news by clicking button below.


Investors and Media

Sign up for Aridis Pharmaceuticals email alerts here.

Contact Us

Aridis Pharmaceuticals respects the privacy of our visitors to our website. By accessing or submitting information through our website, you agree to the terms of this Privacy Policy.

Aridis Pharmaceuticals Inc.
5941 Optical Court
San Jose, CA 95138
Phone: 408-385-1742
Fax: 408-960-3822